A Study of Xilonix for Improving Survival in Colorectal Cancer

ABSTRACT: Primary objectives: Overall survival (OS) will be the primary endpoint of this study, which will be measured from the date of randomization until death or last follow-up. Primary endpoints: Overall survival (OS)

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2531542 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR